Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fabrinet — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.94 (market cap $29.60B), while Fabrinet trades at $581.02 (market cap $18.84B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fabrinet is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FN | |
|---|---|---|
Market Cap | $29.60B | $18.84B |
Sector | Health | Technology |
52-Week High | $491.22 | $746.47 |
52-Week Low | $205.48 | $277.04 |
Enterprise Value | $27.56B | $17.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Fabrinet (FN) trades at $583.95, up 10.79% in 24 hours, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42 billion in 2025, with a net income margin of 9.94%, while the company maintains a debt-free balance sheet and strategic positioning in AI optical supply chains.
Outlook is positive due to robust AI-driven demand and expansion plans, though risks include premium valuation (P/E 45.18) and supply chain constraints. Analysts are bullish with 75% buy ratings and a $661.75 price target (MarketBeat, 2026-07-07), but technical indicators suggest near-term resistance near $532.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
